Alzheimer's Disease Genetics Study
This study aims to find the genes that cause Alzheimer's disease (AD). Researchers are collecting genetic material from families where multiple members have been diagnosed with AD or other forms of dementia. To join, you need to have two living family members diagnosed with AD or dementia, and be able to provide biological samples like fresh blood, cell lines, or frozen brain tissue. The goal of this study is to gather these samples and share them with other qualified researchers to help advance understanding of AD genetics. The current status of this study is unclear.
- Study design
- This is an observational study planning to enroll 10,000 participants. It is not testing a specific intervention or drug.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will contact investigators annually for updates on progress and publication status, but participant follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Alzheimer's Disease Genetics Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Tatiana M. Foroud, PhD · PRINCIPAL_INVESTIGATOR · National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Distribute biological specimens to qualified investigators for use in their research studies.Contact investigators annually for an update on progress and publication status.
Investigators will analyze the samples and publish de-identified results. These publications will help to further the knowledge in the field of dementia and potentially lead to new therapies and targets for therapies.